Member Info for BuenaVista

What news do you think AFC should have released?

that their RNS went out as a press release on Business Wire? Should someone tell them on Twitter?

You've got me at it now!

DE 5

The EU stuff on that.
https://www.google.com/search?q=eu+animal+antibodies

DX to meld with Aptamer and Abingdon (The AAA Health Group), TX to acquire Autolus (Avactolus). Strategy sorted. :o))

Looking like they're preparing to split the company into two. Or there's a different strategy.

packaging, not purchasing!

There's a difference between approval and bringing to market. A lot of work needed for supply chain, manufacturing, purchasing, distribution, etc. Hell, AVA6000 hasn't even got a generic name yet, let alone a brand name!

https://endpts.com/fda-spells-out-how-cancer-drug-developers-can-use-one-trial-for-both-accelerated-and-full-approvals/

^ Can blame Avacta for not tying the AVA3996 preclinical data to the earlier AVA6000 preclinical data and subsequent clinical data that is proving the platform. If Avacta don't make these connections clear in their RNS, the scribblers of analyses like this one will miss the real picture as they're not going to go searching for the background context to the RNS.

A rehash of the RNS without really understanding what it's all about! Such views of the news are what 'the market' sees, hence Avacta continues to go under the radar, when not just seen as held up by red lights.

Sadly Point forgot to mention anything about CanSEEK.

But AVA3996's warhead, AVA272D, is a NCE and so will need to undergo full clinical evaluation and that will take a long time as there will be no shortcuts like there are with AVA6000's doxorubicin and no ODD with its 7-year market exclusivity from product approval unless proteasome inhbitors are used or can be used for 'rare' cancers.

Tumor is how it appears in the abstract. Maybe had to use that spelling to be accepted? ;0) Or done to suppress the fact that the company is not American? ;0)

I hope Alan is watching in to see how every little nuance in the wording of the RNS is being interpreted!

My thought: Does capitalising words that aren't normally capitalised make them sound more important?

The psychology and childish behaviour on show on this board is endlessly fascinating. Haven't read what was written but it sounds as though it was par for the course.

I hope your op goes well on Thursday Touk you old fart and wish you a speedy recovery.

Do we know that the maximum lifetime cumulative exposure is calculated on systemic exposure? The company hasn't said so as far as I know and it's a more complicated calculation than just using what was administered. I can't help the feeling that to base the exposure on systemic doxorubicin introduces an element of uncertainty about how much free doxorubicin an individual patient is generating due to differences in genetics or cancer type or even the presence of FAP elsewhere in the body. There will always be outliers and everyone will want to err on the side of caution, particularly Avacta to avoid the danger litigation.

Andrew Saunders said that there have been patients (plural) receiving AVA6000 out to 8 cycles. To stay under the maximum lifetime cumulative of 450 or even 550mg/m² that could only have been the two anthracycline-naive patients in C1 where 8 cycles would be 432mg/m² of doxorubicin.

DE4

Previously

As at 27th January 2023 the company has 269,961,549 ordinary shares of 10p each in issue.
1.7% of the ordinary shares of the Company are not held in public hands.
Avacta Group has not applied or agreed to have any of its securities (including its AIM securities) admitted or traded on any other exchanges or trading platforms.
There are no restrictions on the transfer of Avacta Group plc’s AIM securities.
Avacta Group plc is subject to the UK City Code on Takeovers and Mergers.
Avacta Group plc is incorporated in the United Kingdom and its principal place of operation is the United Kingdom.
This information was last updated on 27th January 2023.

Now

As at 24th March 2023 the company has 272,436,716 ordinary shares of 10p each in issue.
1.7% of the ordinary shares of the Company are not held in public hands.
Avacta Group has not applied or agreed to have any of its securities (including its AIM securities) admitted or traded on any other exchanges or trading platforms.
There are no restrictions on the transfer of Avacta Group plc’s AIM securities.
Avacta Group plc is subject to the UK City Code on Takeovers and Mergers.
Avacta Group plc is incorporated in the United Kingdom and its principal place of operation is the United Kingdom.
This information was last updated on 24th March 2023.

Everything else the same

Well that doesn't bode well does it. Over 9 weeks to find the first patient for the cohort.

Nah, I think the delay in starting C5 is mainly down to submission of changes to the Phase 1 protocol, possibly waiting for FDA funding for the expensive US sites and guidance on design for Accelerated Approval, conceivably lining up resources at a further 12 sites ready for Phase 1b, and waiting for a month with L in it.